This post was originally published on this site
https://i-invdn-com.akamaized.net/trkd-images/LYNXMPEH2N18Q_L.jpgGSK said the termination of Slaoui’s contract at Galvani Bioelectronics was with immediate effect. Slaoui, the former chief adviser to the U.S. COVID-19 vaccine development programme known as Operation Warp Speed, was not immediately reachable for comment by telephone and LinkedIn (NYSE:LNKD) account.
GSK said an investigation of Slaoui’s conduct had substantiated allegations of harassment and inappropriate contact and the probe was ongoing.
The termination of Slaoui’s contract follows receipt of a letter containing the allegations of inappropriate conduct towards the employee of GSK, the company said. GSK said the allegations stemmed from when Slaoui was an employee of GSK.
Galvani is a bioelectronic medicines set up in 2016 by GlaxoSmithKline (NYSE:GSK) and verily, the life sciences unit of Google parent Alphabet (NASDAQ:GOOGL).
Prior to his role at Galvani, Slaoui spent nearly 30 years at GlaxoSmithKline holding various leadership roles including Head of Pharmaceutical R&D and Chairman of its Vaccines division.